

CONTROLLED SUBSTANCE MODIFICATIONS

2011 GENERAL SESSION

STATE OF UTAH

Chief Sponsor: Gage Froerer

Senate Sponsor: Allen M. Christensen

LONG TITLE

Committee Note:

The Health and Human Services Interim Committee recommended this bill.

General Description:

This bill modifies provisions relating to the Utah Controlled Substances Act by creating a controlled class of listed synthetic cannabinoid substances found in products often referred to as "spice."

Highlighted Provisions:

This bill:

▶ expands the definition of a controlled substance to include a list of synthetic equivalent cannabinoid substances and their analogs and homologs found in products commonly referred to as "spice";

§→ ▶ expands the definition of a controlled substance to include substances and their analogs and homologs found in products referred to as "bath salts;" ←§

▶ clarifies that the tetrahydrocannabinols in Schedule I of the Utah Controlled Substances Act include those both naturally and synthetically derived;

▶ provides that it is an affirmative defense that the person produced, possessed, or administered any of these listed substances if the person:

- was engaged in medical research; and
- was a holder of a license to possess controlled substances for research;

▶ authorizes the Controlled Substances Advisory Committee to recommend placement of a substance on a controlled substance list if it finds that the substance has a potential for abuse and that an accepted standard has not been established for



1113 controlled substances:

- 1114 (1) AM-694;1-[(5-fluoropentyl)-1H-indol-3-yl]-(2-iodophenyl)methanone;
 1115 (2) CP 47,497 and its C6, C8, and C9 homologs; 2-[(1R,3S)-3-hydroxycyclohexyl]
 1116 -5-(2-methyloctan-2-yl)phenol;
 1117 (3) HU-210; (6aR,10aR)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)
 1118 -6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol;
 1119 (4) HU-211; Dexanabinol,(6aS,10aS)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-
 1120 methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol;
 1121 (5) JWH-015; (2-methyl-1-propyl-1H-indol-3-yl)-1-naphthalenyl-methanone;
 1122 (6) JWH-018; Naphthalen-1-yl-(pentylindol-3-yl)methanone {also known as
 1123 1-Pentyl-3-(1-naphthoyl)indole};
 1124 (7) JWH-019; 1-hexyl-3-(1-naphthoyl)indole;
 1125 (8) JWH-073; Naphthalen-1-yl(1-butylindol-3-yl)methanone {also known as
 1126 1-Butyl-3-(1-naphthoyl)indole};
 1127 (9) JWH-081; 4-methoxynaphthalen-1-yl-(1-pentylindol-3-yl)methanone;
 1128 (10) JWH-122; CAS#619294-47-2; (1-Pentyl-3-(4-methyl-1-naphthoyl)indole);
 1129 (11) JWH-200; 1-(2-(4-(morpholinyl)ethyl))-3-(1-naphthoyl) indole;
 1130 (12) JWH-250; 1-pentyl-3-(2-methoxyphenylacetyl)indole;
 1131 (13) JWH-251; 2-(2-methylphenyl)-1-(1-pentyl-1H-indol-3-yl)-ethanone;
 1132 (14) JWH-398; 1-pentyl-3-(4-chloro-1-naphthoyl)indole; ~~§~~ → [and] ← ~~§~~
 1133 (15) RCS-8; 1-(2-cyclohexylethyl)-3-(2-methoxyphenylacetyl)indole {also known as
 1134 BTW-8 and SR-18} ~~§~~ → [;] ;
 1134a **(16) 4-methylmethcathinone {also known as mephedrone};**
 1134b **(17) 3,4-methylenedioxypyrovalerone {also known as MDPV};**
 1134c **(18) 3,4-Methylenedioxymethcathinone {also known as methylone};**
 1134d **(19) 4-methoxymethcathinone;**
 1134e **(20) 4-Fluoromethcathinone; and**
 1134f **(21) 3-Fluoromethcathinone. ←~~§~~**

1135 Section 7. Section **58-37-6** is amended to read:

1136 **58-37-6. License to manufacture, produce, distribute, dispense, administer, or**
 1137 **conduct research -- Issuance by division -- Denial, suspension, or revocation -- Records**
 1138 **required -- Prescriptions.**

1139 (1) (a) The division may adopt rules relating to the licensing and control of the
 1140 manufacture, distribution, production, prescription, administration, dispensing, conducting of
 1141 research with, and performing of laboratory analysis upon controlled substances within this
 1142 state.

1143 (b) The division may assess reasonable fees to defray the cost of issuing original and